Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM

Safety and quality of life assessment, how do they impact patient decision? KCCure survey – part B

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

CAR-T, bispecifics or ADCs in late-stage RRMM

Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI

Treatment of multiple myeloma in Turkey

Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma

Grand Rounds: Improving quality of patient-centred care

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer